Yulin Mo | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Dr. Yulin Mo | Pharmaceutical Science | Best Researcher Award

Shanghai University, China

Mo Yulin is an accomplished researcher and medical professional specializing in pharmacology and traditional Chinese medicine. Born in 1986 in Hezhou, Guangxi, China, he currently serves as a physician at Nanning Hospital of Traditional Chinese Medicine. With over a decade of clinical and research experience, Mo combines medical practice with scientific inquiry, focusing on the mechanistic basis of bone diseases such as glucocorticoid-induced osteoporosis (GIO). He obtained his Master of Medical Science degree in Pharmacology from Guangdong Medical University, where he cultivated a strong foundation in experimental pharmacology, molecular techniques, and data analysis. His academic journey began at Youjiang Medical University for Nationalities, where he earned his Bachelor’s degree in Clinical Medicine. Mo Yulin has actively contributed to several nationally funded research projects and has co-authored high-impact journal articles. His work focuses on the intersection of Traditional Chinese Medicine and modern pharmacological research, particularly targeting bone-related diseases. With a sound understanding of laboratory protocols, animal models, and statistical software, he continues to contribute to both clinical and academic advancements. Mo’s research is well-recognized in peer-reviewed journals and by national scientific foundations, reinforcing his potential as a leading figure in integrative medical research.

Professional Profile

Education

Mo Yulin’s educational background is rooted in a solid blend of clinical and pharmacological sciences. He began his academic journey at Zhaoping County Middle School, completing his secondary education in 2004. He then enrolled at Youjiang Medical University for Nationalities in September 2005, where he pursued a Bachelor’s degree in Clinical Medicine and graduated in June 2010. His interest in the theoretical underpinnings of medicine and drug mechanisms led him to pursue postgraduate studies in Pharmacology. In September 2016, he was admitted to Guangdong Medical University, a recognized institution in medical sciences, where he undertook a full-time Master’s program in Medical Science with a concentration in pharmacology. He completed this program in June 2019. His master’s thesis, titled “Exploring the pathogenesis of GIO and the intervention effect of Danshensu based on TXNIP mediated mitochondrial oxidative phosphorylation,” demonstrated a deep integration of molecular biology, pharmacology, and traditional Chinese medicine. His academic record is also supplemented by participation in various specialized training programs and international summer courses, including workshops on stem cell biology and network pharmacology. This extensive and interdisciplinary academic training has equipped him with a broad understanding of clinical medicine, experimental design, and the pharmacological sciences.

Professional Experience

Mo Yulin has built an impressive career that bridges clinical practice and biomedical research. His professional journey began in June 2010 when he joined the Nanning Hospital of Traditional Chinese Medicine as a medium physician in the Internal Medicine and Physical Examination departments. Over six years in this role, he developed a strong clinical foundation and a growing interest in disease mechanisms and pharmacological interventions. After obtaining his Master’s degree, he returned to the same hospital in June 2019, this time focusing on a broader medical department, where he continues to practice medicine. During his tenure, Mo has maintained a dual focus on patient care and experimental research, allowing him to apply his laboratory insights to real-world medical challenges. He has collaborated with senior professionals and contributed to national-level research, while also mentoring younger colleagues in clinical routines and laboratory practices. His unique ability to translate bench-side findings to bedside interventions highlights his effectiveness as both a clinician and a researcher. With over a decade of continuous professional involvement in the medical field, Mo has shown commendable commitment, especially in the integration of traditional Chinese therapies with modern biomedical strategies.

Research Interest

Mo Yulin’s research interests lie primarily at the intersection of traditional Chinese medicine and modern pharmacological science, with a particular emphasis on bone-related disorders and oxidative stress mechanisms. He is especially passionate about understanding and treating glucocorticoid-induced osteoporosis (GIO) using molecular and cellular approaches. His master’s thesis explored the TXNIP-mediated mitochondrial oxidative phosphorylation pathway as a contributor to bone loss, representing a critical nexus of energy metabolism and bone pathology. Mo is also interested in the pharmacological potential of natural Chinese medicine, including monomer compounds and complex formulations, to treat chronic diseases such as osteoporosis, vascular diseases, and diabetes. Another area of interest includes modeling disease conditions in animals—he has mastered several techniques to establish experimental models, including ovariectomized rats and glucocorticoid-induced fracture models. Additionally, Mo is fascinated by the application of bioinformatics and network pharmacology to identify active compounds in traditional medicines and link them to molecular targets. His broader academic pursuit is to modernize traditional therapies by uncovering their mechanisms of action at the cellular and genetic level. By combining ancient medical wisdom with cutting-edge scientific techniques, he aims to contribute to integrative medicine and develop more effective, evidence-based therapeutic strategies.

Research Skills

Mo Yulin possesses a comprehensive skill set spanning molecular biology, pharmacological modeling, histology, and data analytics. He is highly proficient in conducting experiments involving animal models, particularly in the induction of osteoporosis and bone fractures in rodents. His technical skills include the extraction and culturing of bone marrow mesenchymal stem cells, human osteosarcoma cell lines, and various molecular biology assays like Western blotting, RT-qPCR, MTT assays, plasmid transfection, and siRNA interference. He is also skilled in bone histomorphometry, micro-CT analysis, and both decalcified paraffin and non-decalcified plastic embedding techniques. Mo is adept at performing immunohistochemistry and various types of staining for microscopic analysis. In addition to wet-lab skills, he is well-versed in statistical analysis and scientific computing using software such as SPSS, GraphPad Prism, and ImageJ. His ability to combine laboratory expertise with data interpretation and literature synthesis makes him a competent and independent researcher. Furthermore, he is capable of integrating traditional Chinese medicine theory with modern biochemical analysis, allowing for novel insights into drug mechanisms. These versatile research skills equip him to work on multidisciplinary projects in both academic and clinical research settings.

Awards and Honors

Throughout his academic and professional career, Mo Yulin has been recognized for his analytical acumen and research capability. During his undergraduate studies, he participated in the National College Students Mathematical Modeling Competitions, where he won the second prize in 2006 (Guangxi B group) and the third prize in 2007 (Guangxi group A). These early accomplishments reflected his strong foundation in analytical thinking and a keen interest in applying quantitative methods to solve biomedical problems. Later, his master’s thesis was selected for review by the Academic Degrees Committee of Guangdong Province, a sign of academic excellence. In addition, Mo has participated in several prestigious training programs and conferences, such as the Croucher Foundation’s summer course on Stem Cell Biology and Regenerative Medicine at the Chinese University of Hong Kong. He was also selected for training in Network Pharmacology Technology of Traditional Chinese Medicine and participated in the 9th International Academic Conference on Osteoporosis and Bone Mineral Salt Diseases, contributing to his professional growth and global exposure. These accolades, combined with his inclusion as a project participant in national-level funded research, highlight his growing stature as a serious and capable biomedical researcher.

Conclusion

In conclusion, Mo Yulin is a highly capable and dedicated researcher with a unique profile that bridges clinical medicine and pharmacological science, especially within the framework of Traditional Chinese Medicine. His academic achievements, research capabilities, and publication record affirm his suitability for a distinguished research career. He has already contributed valuable insights into the understanding and treatment of bone-related disorders and oxidative stress, demonstrated by peer-reviewed publications in high-impact journals and successful participation in national research projects. Mo’s well-rounded expertise, from cell culture and animal modeling to statistical data analysis and Chinese medicinal compound evaluation, gives him a holistic view of disease pathology and therapeutic mechanisms. Although a Ph.D. degree and more international collaborations could further enhance his research impact, his current contributions and potential for future work are substantial. Mo Yulin is not only a skilled physician but also a thoughtful researcher whose work continues to bridge gaps between traditional knowledge and modern science. Based on his achievements and potential, he stands out as a strong candidate for the Best Researcher Award.

Publications top Notes

  1. TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis
    Authors: Yulin Mo, Wenxiu Lai, Ying Zhong, Zhuoqing Hu, Meigui You, Minqun Du, Pan Wang, Xinyou Wu, Cailing Chen, Huanmin He, Zhimin Gao, Yaping Xu, Dongtao Wang, Liao Cui, Yajun Yang
    Year: 2021
    Journal: Life Sciences 266 (2021): 118938
  2. Tanshinol alleviates microcirculation disturbance and impaired bone formation by attenuating TXNIP signaling in GIO rats
    Authors: Wenxiu Lai, Yulin Mo, Dongtao Wang, Ying Zhong, Lujiao Lu, Jiajia Wang, Liao Cui, Yanzhi Liu, Yajun Yang
    Year: 2021
    Journal: Frontiers in Pharmacology, 12: 722175
  3. The mechanism of TXNIP-mediated oxidative stress in the disease
    Authors: Mo Yulin, Yang Yajun, Cui Liao
    Year: 2018

 

 

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry

 

 

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Ms. Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

University CEU CArdenal Herrera, Spain

Phuong Linh Ta is an emerging researcher in the field of pharmacology, currently pursuing her doctoral studies at Universidad Cardenal Herrera CEU in Spain. She is a highly motivated scientist with a solid academic foundation and practical experience in pharmaceutical research, particularly focusing on ocular drug delivery systems and antibiotic discovery. Throughout her career, she has actively contributed to impactful projects that address pressing global health concerns, such as the development of new antibiotics and the prevention of cognitive decline associated with diseases like Alzheimer’s. She has consistently demonstrated a passion for contributing to both scientific advancement and community well-being through her involvement in various outreach programs including elderly care and sustainable development challenges. Phuong Linh Ta’s scientific journey is marked by a balanced integration of academic excellence, innovative research, and social engagement. Her participation in prestigious conferences across Europe has allowed her to present her work to the international scientific community, thereby expanding her professional network and research visibility. With her commitment to continuous learning, interdisciplinary collaboration, and practical applications in the pharmaceutical field, Phuong Linh Ta is steadily building a robust research portfolio that holds promise for future breakthroughs in pharmacology and clinical applications.

Professional Profile

Education

Phuong Linh Ta’s educational background showcases a steady progression in pharmaceutical sciences and clinical research. She completed her Master’s degree in Direction and Monitorization of Clinical Trials from Universidad Cardenal Herrera CEU in 2022, equipping her with specialized knowledge in clinical trial design and pharmaceutical study management. Prior to that, she earned her Bachelor’s degree in Pharmacy from the same university in 2021, which provided her with a strong foundation in pharmacological principles, drug formulation, and patient care. She also participated in the Forster Summer School at the University of Mainz in 2019, where she gained international exposure and broadened her academic perspective. Her early academic journey includes completing the International Baccalaureate at Birkerød Gymnasium, HF, IB & Boarding School in Denmark, which highlights her global educational experience. This diverse and international academic pathway has given her a broad cultural and scientific outlook, enhancing her adaptability and communication across different educational and professional environments. Her formal education has been consistently aligned with her research interests, particularly in clinical pharmacology, drug delivery systems, and public health, positioning her well for her doctoral research and future contributions to the pharmaceutical sector.

Professional Experience

Phuong Linh Ta has developed substantial professional experience through various academic roles at Universidad Cardenal Herrera CEU. She is currently engaged as a doctoral student in the Faculty of Pharmacy, focusing on pharmacology research, with her work beginning in November 2022. Her previous roles include serving as a Pharmacy Classroom Assistant, where she provided educational support and facilitated learning for undergraduate students. Additionally, she worked as an Internal Student in the Department of Pharmacology, where she honed her laboratory and research skills through hands-on involvement in pharmaceutical studies. Her collaborative roles in the departments of Languages and Communication further enriched her interpersonal, administrative, and organizational capabilities, demonstrating her versatility and commitment to contributing to different facets of the university environment. These experiences have provided her with a well-rounded understanding of both research and academic operations, preparing her for independent and collaborative work in complex scientific projects. Her sustained professional engagement within the same institution illustrates her reliability, long-term dedication, and growth within the academic community. Her evolving responsibilities have enabled her to build a solid foundation in both teaching and research, setting the stage for her continued contributions to the field of pharmacology.

Research Interest

Phuong Linh Ta’s primary research interests lie at the intersection of pharmacology, drug delivery systems, and clinical applications aimed at improving patient outcomes. She is particularly focused on the development of ocular drug delivery platforms, including the formulation and characterization of ocular inserts to enhance the bioavailability and targeted release of therapeutic agents. Her recent research has concentrated on using alpha-lipoic acid in beta-cyclodextrin complexes for improved delivery to the posterior segment of the eye, which holds significant potential for the treatment of ocular diseases and the prevention of long-term complications associated with high myopia. Additionally, she has been involved in projects that address global health challenges such as the discovery of new antibiotics and the promotion of their rational use, aligning her work with the global fight against antimicrobial resistance. Her interest extends to neuroprotective strategies for the early prevention of cognitive deterioration, reflecting her multidisciplinary approach that bridges pharmaceutical technology with public health priorities. Phuong Linh Ta’s research is deeply rooted in translating laboratory findings into practical healthcare solutions, and she is committed to advancing drug delivery science to make therapeutics more efficient, accessible, and patient-centered.

Research Skills

Phuong Linh Ta possesses a diverse range of research skills that are crucial to her contributions in pharmaceutical sciences. She is proficient in developing and characterizing drug delivery systems, particularly ocular inserts, and has significant experience in in vitro release studies and ex vivo diffusion studies. Her technical expertise includes working with complex molecular assemblies like beta-cyclodextrin complexes, optimizing drug stability and bioavailability. She is skilled in conducting clinical trials, managing pharmacological experiments, and applying service-learning methodologies in educational and research settings. Her involvement in competitive R&D projects has also equipped her with skills in project planning, data analysis, and scientific reporting. Furthermore, she has effectively communicated her research findings at multiple international conferences, indicating her capability in scientific presentation and knowledge dissemination. Phuong Linh Ta’s multilingual abilities—fluency in Vietnamese, Spanish, and English—further enhance her collaborative potential in diverse research environments. Her capacity to integrate laboratory research with clinical applications and her aptitude for both independent and team-based work make her a versatile and competent researcher. She continuously seeks to refine her laboratory techniques, analytical skills, and knowledge of pharmacological systems to remain at the forefront of her field.

Awards and Honors

As of the current stage of her career, Phuong Linh Ta’s recognition is primarily reflected in her selection for multiple competitive research projects and her invitations to present at prestigious scientific conferences across Europe. She has actively participated in national and international conferences such as EVER, the Controlled Release Society (CRS) Annual Meeting, and the Spanish-Portuguese Conference on Controlled Drug Delivery. These platforms have provided her with opportunities to showcase her research and gain valuable feedback from global experts. Her consistent involvement in the SWI@CEU project and the DeCo MICOF-CEU project demonstrates the trust her academic institution places in her research capabilities. While she has not yet accumulated formal awards or fellowships, her current academic track record and research engagement highlight her potential for future recognition and academic distinction. Participation in such competitive and high-impact research initiatives serves as an important professional milestone, indicating her emerging status within the scientific community. Moving forward, continued success in publishing peer-reviewed articles and leading independent research projects will likely pave the way for her to receive more significant awards, grants, and honors that will further validate her contributions to pharmaceutical sciences.

Conclusion

Phuong Linh Ta is a dedicated and promising researcher who has steadily built a strong foundation in pharmacology and pharmaceutical research through her education, professional experience, and focused scientific contributions. Her work reflects a commitment to developing innovative drug delivery systems, with particular emphasis on ocular therapeutics and public health impact. While her research is still in the early stages, she has already gained substantial international exposure and actively contributed to community-based and service-learning projects. Her technical skills, multilingual proficiency, and ability to collaborate in multidisciplinary teams make her well-prepared to take on more advanced research challenges in the future. Although there are areas for growth, especially in peer-reviewed publications and leadership of independent projects, her trajectory suggests she is on the right path toward becoming a highly impactful researcher. With further development and continued dedication, Phuong Linh Ta has the potential to significantly contribute to advancements in drug delivery, pharmacology, and patient-centered healthcare solutions. Her work is aligned with global health priorities, and she is well-positioned to make meaningful scientific contributions in both academic and clinical contexts.

Publications Top Notes

  • Title: Optimization and Validation of a High‐Performance Liquid Chromatography (HPLC‐UV) Method for Quantification of α‐Lipoic Acid in Cyclodextrins Complex for Ocular Delivery

  • Authors: Phuong Linh Ta, Lucia Bernat‐Just, Adrián M. Alambiaga‐Caravaca, Vicent Rodilla, Alicia López‐Castellano, Francisco Bosch‐Morell

  • Year: 2025

Mohammad Reza Khazdair | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Assoc. Prof. Dr. Mohammad Reza Khazdair | Pharmaceutical Science | Best Researcher Award

Physiology and Pharmacology from Birjand University of Medical Sciences, Iran

Dr. Mohammad Reza Khazdair is an accomplished researcher and academic specializing in clinical physiology, respiratory pharmacology, and the therapeutic potential of medicinal plants. With a strong background in airway pharmacology, he has dedicated his research to investigating the effects of medicinal plants on respiratory and neurological systems, particularly focusing on asthma, tracheal smooth muscle relaxation, and occupational respiratory diseases. His expertise is recognized through his leadership roles, including Deputy Director of the Cardiovascular Disease Research Center at Birjand University of Medical Sciences. Dr. Khazdair has actively contributed to the scientific community as an editor and reviewer for several prestigious journals and has demonstrated innovation through patented herbal formulations. His consistent recognition as Best Researcher and his influence in respiratory pharmacology highlight his valuable contributions to advancing medical science in Iran and beyond. In addition to his research work, he has successfully managed multiple medical journals, coordinated research projects, and mentored young scientists. His academic journey and diverse professional roles emphasize his commitment to the continuous growth of clinical and pharmacological research. Dr. Khazdair’s career is marked by a unique blend of scientific excellence, editorial leadership, and a passion for integrating traditional medicine into modern clinical practice.

Professional Profile

Education

Dr. Mohammad Reza Khazdair pursued his academic journey with dedication and a clear focus on life sciences and medical research. He began his primary education in Jafarabad, Khorasan, Iran, between 1990 and 1995, followed by middle school in Torbat Jam from 1995 to 1998. His secondary education was completed at Torbat Jam High School between 1998 and 2001. Dr. Khazdair obtained his Bachelor of Science degree in Biology from the Islamic Azad University, Mashhad, Iran, in 2005. He further advanced his studies by earning a Master of Science degree in Biology from Shahid Bahonar University of Kerman in 2010, where he deepened his knowledge in biological sciences. Driven by a strong interest in pharmaceutical research, he completed his Ph.D. at the Pharmaceutical Research Center, Mashhad University of Medical Sciences, in 2018. His doctoral studies focused on the pharmacological effects of medicinal plants and their applications in treating respiratory diseases. The combination of his biology and pharmaceutical training has provided him with a solid foundation to conduct advanced interdisciplinary research. Dr. Khazdair’s academic qualifications have significantly shaped his career in clinical physiology and have equipped him with the expertise necessary to pursue innovative research in his field.

Professional Experience

Dr. Mohammad Reza Khazdair’s professional journey is distinguished by a diverse range of academic, administrative, and editorial roles in reputable Iranian medical institutions. His career began as a Lecturer in Clinical Physiology at Torbat Jam Faculty of Medical Sciences in 2018, where he quickly rose to positions of responsibility, including Dean of Clinical Research Development Units and Student-Cultural Director. Since August 2019, he has been serving as an Assistant Professor in Clinical Physiology at the Cardiovascular Diseases Research Center, Birjand University of Medical Sciences. His leadership extends to his role as Deputy Director of the Cardiovascular Disease Research Center. Dr. Khazdair has been instrumental in advancing several medical journals, serving as Manager Editor and Associate Editor for publications such as the Journal of Birjand University of Medical Sciences, Modern Care Journal, and the Journal of Surgery and Trauma. His editorial experience includes managing special issues and contributing to the development of journals within the medicine and health portfolios. Additionally, he has served as a reviewer for numerous high-impact international journals. His ability to combine research, teaching, journal management, and scientific leadership reflects his multifaceted contribution to the academic and medical research community.

Research Interest

Dr. Mohammad Reza Khazdair’s research interests are primarily focused on clinical physiology with an emphasis on respiratory diseases and the pharmacological activities of medicinal plants. His work delves into airway pharmacology, particularly in asthma, exploring the regulatory mechanisms that influence respiratory function. He has a deep interest in studying the relaxant effects of medicinal plants on tracheal smooth muscles and has conducted extensive investigations into the potential therapeutic applications of natural compounds in managing respiratory conditions. Additionally, his research addresses occupational respiratory diseases and the adverse effects of environmental pollution on lung health. Dr. Khazdair’s innovative approach integrates traditional medicine with modern pharmacology, aiming to discover alternative treatments for respiratory and neurological disorders. His work has also extended into the evaluation of medicinal plants on the nervous system, further highlighting his interdisciplinary expertise. This diverse research portfolio is supported by his active engagement in both laboratory and clinical studies, where he continuously seeks to translate his findings into practical therapeutic strategies. His commitment to respiratory health and phytomedicine underscores his significant contribution to the growing body of evidence supporting the use of natural products in modern clinical applications.

Research Skills

Dr. Mohammad Reza Khazdair possesses a broad set of research skills that have been honed through years of academic study and professional practice. His expertise in pharmacology, particularly in studying airway responses and smooth muscle physiology, has enabled him to design and conduct complex in vitro and in vivo experiments. He is skilled in the extraction and analysis of bioactive compounds from medicinal plants and in determining their pharmacological effects on respiratory and neurological systems. Dr. Khazdair is also proficient in scientific writing, having authored and reviewed numerous articles across internationally recognized journals. His editorial leadership has provided him with a deep understanding of peer review processes, journal management, and the publication of high-impact research. He has strong project management skills, successfully overseeing journal portfolios and coordinating editorial teams. Dr. Khazdair’s experience also includes managing research centers, mentoring young researchers, and fostering collaborations across disciplines. His ability to critically analyze scientific data, develop innovative hypotheses, and apply rigorous methodologies in pharmacological research demonstrates his advanced capabilities. His comprehensive skill set positions him as a valuable contributor to both academic and applied research in clinical physiology and phytomedicine.

Awards and Honors

Dr. Mohammad Reza Khazdair’s outstanding research contributions have earned him several prestigious awards and recognitions throughout his career. In 2016, he was honored with the First Prize in Research in Basic Medical Sciences by the School of Pharmacy at Mashhad University of Medical Sciences, recognizing his pioneering work in the pharmacological effects of natural products. His excellence in research was further acknowledged in 2022 when he was selected as a top researcher in Southern Khorasan Province, Iran. The same year, he received the Best Researcher Award at the Birjand University of Medical Sciences Research Festival, a recognition he successfully earned again in 2024. These consistent accolades highlight his sustained commitment to advancing scientific knowledge, particularly in respiratory pharmacology and phytomedicine. His recognized patents, including a syrup and capsule formulation from Zataria multiflora and Carvacrol, further validate the practical and innovative aspects of his research. Dr. Khazdair’s awards reflect not only his scientific excellence but also his impact on healthcare development and natural product applications in Iran. His achievements underscore his dedication to producing high-quality research that bridges the gap between traditional medicine and modern clinical practice.

Conclusion

Dr. Mohammad Reza Khazdair has established himself as a highly competent and innovative researcher in the field of clinical physiology, with a particular focus on respiratory pharmacology and the therapeutic potential of medicinal plants. His academic journey, professional experience, and substantial contributions to the editorial management of scientific journals showcase his diverse expertise and leadership within the medical research community. His work addresses critical health issues such as asthma, occupational respiratory diseases, and the harmful effects of environmental pollutants, providing significant insights into alternative treatment strategies. Dr. Khazdair’s recognition as Best Researcher on multiple occasions, along with his involvement in high-impact journals and successful patent registrations, demonstrate his commitment to scientific advancement and healthcare innovation. While expanding his international collaborations and focusing on clinical trials could further enhance his global research influence, his current achievements already position him as an impactful and dedicated contributor to medical science. His ability to integrate traditional medicinal knowledge with modern pharmacological methods exemplifies a valuable and forward-thinking approach to healthcare research. Dr. Khazdair’s career trajectory reflects continuous growth, high scientific standards, and meaningful contributions to both academia and clinical practice.

Publications Top Notes

  1. Title: Crocus sativus (Saffron): A potential multifunctional therapeutic agent for neurodegenerative disorders

    • Authors: M.R. Khazdair, Mohammad Reza

    • Year: 2024

  2. Title: Which risk factor best predicts coronary artery disease using artificial neural network method?

    • Authors: N. Azdaki, Fatemeh Salmani, Toba Kazemi, S.A. Moezi Bady, M.R. Khazdair

    • Year: 2024

    • Citations: 6

  3. Title: The Monitoring of Serum and Urine heavy Metals and assessment of inflammatory response, Respiratory Symptoms, and Pulmonary health in Cement-Exposed Workers

    • Authors: Majid Firouzi, M.R. Khazdair, V.R. Askari, Zhila Taherzadeh, M.H. Boskabady

    • Year: 2024

  4. Title: Protective effects of carvacrol on lipid profiles, oxidative stress, hypertension, and cardiac dysfunction – A comprehensive review

    • Authors: M.R. Khazdair, Mozhgan Moshtagh, Akbar Anaeigoudari, Shima Jafari, Toba Kazemi

    • Year: 2024

    • Citations: 5

  5. Title: Rosmarinic acid improves tracheal smooth muscle responsiveness and lung pathological changes in ovalbumin-sensitized rats

    • Authors: Vahideh Sadat Abbasnia, Mohsen Foadoddini, Delaram Eslimi Esfahani, M.R. Khazdair, Sharbanoo Oryan

    • Year: 2024

    • Citations: 1

  6. Title: The therapeutic potential of Melissa officinalis L. hydroalcoholic extract and rosmarinic acid in a rat asthmatic model: A study on anti-inflammatory and antioxidant effects

    • Authors: Vahideh Sadat Abbasnia, Delaram Eslimi Esfahani, M.R. Khazdair, Sharbanoo Oryan, Mohsen Foadoddini

    • Year: 2024

    • Citations: 1

  7. Title: Effects of Lamiaceae family plants and their bioactive ingredients on coronavirus-induced lung inflammation

    • Authors: Majid Kianmehr, M.R. Khazdair, Abbasali Abbasnezhad, Muhammad Sohail Akram

    • Year: 2024

    • Citations: 5

  8. Title: The effects of opium consumption on severity of disease on hospitalized COVID-19 patients in East of Iran, a prospective cohort study

    • Authors: Abdol Sattar Pagheh, Toba Kazemi, Seyed Mohammad Riahi, Parisa Vahdati, M.R. Khazdair

    • Year: 2024

Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Prof. Dr. Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Professor-Biochemistry from Avalon Medical School, Curaçao

Dr. Mohamed Fakhry Mohamed Abdelbaky is a distinguished professor of biochemistry with a robust academic and research background spanning over two decades. He earned his PhD in Biochemistry from Glasgow Caledonian University, UK, in 2011, following his MSc and MB.B.Ch from Minya University, Egypt. Dr. Abdelbaky has held significant academic positions across various international institutions, including Avalon University School of Medicine in Curaçao, Texila American University in Guyana, and Al Maarefa University in Saudi Arabia. His roles have encompassed curriculum development, teaching, student evaluation, and administrative leadership. His research interests are diverse, focusing on molecular biology, cancer research, and pharmacological studies, with numerous publications in reputable journals. Dr. Abdelbaky’s commitment to education and research excellence is evident through his active participation in academic committees, mentorship, and continuous professional development. His contributions have significantly advanced the field of biochemistry, making him a valuable asset to the scientific community.

Professional Profile

Education

Dr. Abdelbaky’s educational journey reflects a strong foundation in medical and biochemical sciences. He obtained his Bachelor of Medicine and Surgery (MB.B.Ch) from the Faculty of Medicine, Minya University, Egypt, in 2000. Pursuing his passion for biochemistry, he completed his Master of Science (MSc) in Biochemistry at the same institution in 2006, where his thesis focused on the effects of plasma homocysteine on VEGF levels in platelets and neutrophils. To further enhance his expertise, he pursued a PhD in Biochemistry and Molecular Biology at Glasgow Caledonian University, UK, completing it in 2011. His doctoral research investigated the biological effects of the proto-oncoprotein EVI1 in normal and transformed fibroblasts. This comprehensive educational background has equipped Dr. Abdelbaky with the knowledge and skills necessary to excel in both academic and research settings, contributing significantly to the field of biochemistry.

Professional Experience

Dr. Abdelbaky’s professional career is marked by a series of progressive academic appointments and responsibilities. He began as a Teaching Assistant at Minya University, Egypt, where he was involved in designing and supervising laboratory experiments for medical students. His dedication led to his promotion to Assistant Lecturer and subsequently to Lecturer, where he continued to contribute to teaching and research activities. He expanded his international experience by serving as a Postgraduate Demonstrator at Glasgow Caledonian University, UK, where he supervised laboratory sessions and research projects for science students. Dr. Abdelbaky furthered his academic career as an Assistant Professor at Al Maarefa University in Saudi Arabia, teaching medical biochemistry and genetics to students of various health science programs. He later joined Texila American University in Guyana as an Associate Professor, where he was responsible for curriculum design and delivery of biochemistry and medical genetics courses. Currently, he holds the position of Professor at Avalon University School of Medicine in Curaçao, where he continues to contribute to curriculum development, teaching, and student mentorship. Throughout his career, Dr. Abdelbaky has demonstrated a commitment to academic excellence and leadership in biochemistry education.

Research Interests

Dr. Abdelbaky’s research interests are centered around molecular biology, cancer research, and pharmacological studies. He has a particular focus on understanding the molecular mechanisms underlying various diseases, including cancer and metabolic disorders. His research explores the roles of specific genes and proteins in disease progression and treatment responses. Dr. Abdelbaky is also interested in the development and evaluation of pharmacological agents for disease prevention and therapy. His work often involves investigating the effects of natural compounds and pharmaceuticals on cellular and molecular pathways. Through his research, Dr. Abdelbaky aims to contribute to the development of effective diagnostic and therapeutic strategies for complex diseases, ultimately improving patient outcomes.

Research Skills

Dr. Abdelbaky possesses a comprehensive set of research skills that enable him to conduct advanced studies in biochemistry and molecular biology. He is proficient in tissue culture techniques, allowing for the cultivation and maintenance of various cell lines for experimental purposes. His expertise includes the isolation of DNA, RNA, and proteins, essential for analyzing gene and protein expression. Dr. Abdelbaky is skilled in polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR), techniques crucial for amplifying and studying specific DNA and RNA sequences. He is experienced in gene knockdown methods, which are used to study gene function by reducing gene expression. Additionally, he is adept at performing agarose and polyacrylamide gel electrophoresis (PAGE) for the separation and analysis of nucleic acids and proteins. These technical skills are fundamental to his research endeavors, enabling him to investigate complex biological processes and contribute valuable insights to the field of biochemistry.

Awards and Honors

Throughout his career, Dr. Abdelbaky has received recognition for his contributions to biochemistry and medical education. He is a member of several prestigious professional societies, including the Academy of Medical Educators (AoME) in the UK, the Egyptian Medical Syndicate, and the Egyptian Society of Medical Biochemistry. His active participation in these organizations reflects his commitment to professional development and collaboration within the scientific community. Dr. Abdelbaky has also contributed to the peer-review process for scientific journals, demonstrating his expertise and dedication to maintaining high standards in research publication. His involvement in continuous medical education (CME) programs and attendance at international conferences further highlight his pursuit of knowledge and excellence in his field. These accolades and affiliations underscore Dr. Abdelbaky’s standing as a respected figure in biochemistry and medical education.

Conclusion

Dr. Mohamed Fakhry Mohamed Abdelbaky’s extensive academic background, international teaching experience, and robust research portfolio position him as a leading figure in the field of biochemistry. His dedication to education is evident through his curriculum development efforts, mentorship, and active participation in academic committees. His research contributions have advanced the understanding of molecular mechanisms in disease and informed the development of therapeutic strategies. Dr. Abdelbaky’s technical expertise and commitment to professional growth have earned him recognition within the scientific community. His multifaceted career reflects a blend of academic excellence, research innovation, and leadership, making him a valuable asset to any institution and a strong candidate for accolades such as the Best Researcher Award.

Publications Top Notes

  1. Title: Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III
    Authors: Roy P, Reavey E, Rayne M, Roy S, Abed El Baky M, Ishii Y, Bartholomew C
    Year: 2010

  2. Title: BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Authors: Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C
    Year: 2012

  3. Title: Potential impact of urocortin I on sperm count, motility and sex hormone profiles in normal adult rats
    Authors: Hany A. El Kattawy, Mahmoud A. Naga, Ahmed Shata, Mohamed A. Elbaky
    Year: 2016

  4. Title: PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats
    Authors: MZ Mohamed, MF Abed El Baky, OA Hassan, HH Mohammed, AM Abdel-Aziz
    Year: 2020

  5. Title: The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis
    Authors: Mostafa M. Mohammed, Olfat Shaker, Maggie M. Ramzy, Shereen S. Gaber, Heba S. Kamel, Mohamed F. Abed EL Baky
    Year: 2021

  6. Title: Aprepitant exerts anti-fibrotic effect via inhibition of TGF-β/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Merhan E. Ali, Heba M. Hafez
    Year: 2022

  7. Title: Mirabegron alleviates acetic acid-induced colitis in rats: role of adiponectin and GSTM1/GSH detoxification pathway
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Heba M. Hafez
    Year: 2023

  8. Title: Cardioprotective effect of Ginger in a rat model of myocardial damage and its possible intervention in PERK-ATF4-CHOP-PUMA apoptotic pathway
    Authors: M. M. Mohammed, N. A. A. Osman, F. M. Moura, M. F. Abedelbaky
    Year: 2023

  9. Title: Vinpocetine alleviates valproic acid-induced hepatotoxicity and neurotoxicity through activation of cAMP and PI3K/AKT/CREB pathway in rats
    Authors: Heba M. Hafez, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Salma M. Hassan, Mervat Z. Mohamed
    Year: Under submission (anticipated 2024 or 2025)

Yongpan An | Pharmaceutical Science | Best Researcher Award

Published on by Shen Awards

Dr. Yongpan An | Pharmaceutical Science | Best Researcher Award

Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China

Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.

Professional Profile

Education

Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.

Professional Experience

Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.

Research Interests

Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.

Research Skills

Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.

Awards and Honors

Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.

Conclusion

In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.

Publications Top Notes

  1. Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
    Journal: Biomaterials
    Year: 2025

Carolina Batista | Pharmaceutical Science | Women Researcher Award

Published on by Shen Awards

Dr. Carolina Batista | Pharmaceutical Science | Women Researcher Award

Biomedical from Federal University of Rio de Janeiro, Brazil

Dr. Carolina Batista is a distinguished global health physician with over two decades of experience in humanitarian and public health initiatives. Currently serving as the Head of Global Health Affairs at Baraka Impact Finance, she leverages her medical expertise and strategic insight to foster innovative health solutions for underserved populations. Her career commenced in Brazil, where she provided medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia, Africa, and Latin America, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. As Director of MSF’s Brazilian Medical Unit, she led international campaigns, notably for Chagas disease. Subsequently, at the Drugs for Neglected Diseases initiative (DNDi), she spearheaded access frameworks for NTDs across Latin America, influencing public policies and fostering partnerships. Dr. Batista holds a medical degree from Brazil and a master’s in International Public Health from institutions including the Swiss Tropical and Public Health Institute. Her contributions extend to roles on the International Board of MSF, The Lancet COVID-19 Commission, and as a strategic advisor for ISGlobal, reflecting her commitment to health equity and innovation in global health.

Professional Profile

Education

Dr. Carolina Batista’s educational journey is marked by a blend of clinical training and global public health expertise. She earned her medical degree in Brazil, grounding her in clinical practice and primary healthcare delivery. Pursuing a broader impact, she obtained a master’s degree in International Public Health through a collaborative program involving the Swiss Tropical and Public Health Institute, the Institute of Tropical Medicine in Antwerp, and the Royal Tropical Institute in Amsterdam. This multidisciplinary education equipped her with a comprehensive understanding of global health challenges, particularly in infectious and neglected diseases. Further enhancing her capabilities, Dr. Batista pursued advanced studies in management, health and human rights, and policy and advocacy from renowned institutions. This diverse educational background has been instrumental in her ability to design and implement effective health interventions and policies across various international contexts.

Professional Experience

Dr. Carolina Batista’s professional trajectory encompasses significant roles in global health organizations. Her career began in Brazil, providing medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia and later serving as Director of the Brazilian Medical Unit, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. She led international campaigns, notably for Chagas disease, and coordinated MSF’s medical response to COVID-19 in the Navajo Nation, USA. At the Drugs for Neglected Diseases initiative (DNDi), she served as Head of Access and Medical Affairs, developing access frameworks for NTDs across Latin America. Currently, as Head of Global Health Affairs at Baraka Impact Finance, she supports social entrepreneurs in developing innovative health solutions. Dr. Batista also holds positions on the International Board of MSF and serves as a strategic advisor for ISGlobal

Research Interests

Dr. Carolina Batista’s research interests are deeply rooted in global health equity, focusing on neglected tropical diseases (NTDs), health systems in low- and middle-income countries, and access to healthcare for vulnerable populations. She is particularly interested in the development and implementation of innovative financing mechanisms to achieve the Sustainable Development Goals (SDGs), the role of private capital in bridging healthcare access gaps, and the integration of ethical artificial intelligence in health communication. Her work also explores the intersection of migration and health, pandemic preparedness, and the gender gap in healthcare access. Dr. Batista’s research aims to inform policies and practices that enhance healthcare delivery and accessibility for marginalized communities worldwide.

Research Skills

Dr. Carolina Batista possesses a robust set of research skills that encompass both qualitative and quantitative methodologies. Her expertise includes treatment protocols, health systems analysis, diagnostics, and primary care, particularly concerning parasitic and neglected diseases. She is adept at designing and implementing operational research projects, developing access frameworks, and conducting policy analysis. Her skills extend to evaluating health programs, engaging with stakeholders, and advocating for policy changes. Dr. Batista’s proficiency in these areas enables her to contribute effectively to research initiatives aimed at improving health outcomes in underserved populations.

Awards and Honors

Dr. Carolina Batista’s contributions to global health have been recognized through various appointments and memberships. She serves on the International Board of Médecins Sans Frontières (MSF) and is a strategic advisor for the Barcelona Institute for Global Health (ISGlobal). Her role in leading MSF’s medical response to COVID-19 in the Navajo Nation and her involvement in The Lancet COVID-19 Commission underscore her commitment to addressing health crises. Additionally, she chairs the DNDi Latin America board and serves on the boards of The Lancet Migration Latin America, Movement Health Foundation, and Health in Harmony. These positions reflect her leadership and dedication to advancing health equity and innovation.

Conclusion

Dr. Carolina Batista exemplifies a career dedicated to advancing global health equity through clinical practice, research, and policy development. Her extensive experience with organizations like MSF and DNDi, coupled with her strategic role at Baraka Impact Finance, highlights her commitment to improving healthcare access for marginalized populations. Her educational background and research interests inform her holistic approach to health challenges, integrating innovative solutions with traditional practices. Dr. Batista’s leadership roles and board memberships further demonstrate her influence in shaping global health policies and initiatives. Her work continues to inspire and drive progress towards equitable healthcare worldwide.

Publications Top Notes

1. Exposed Subsoil Under Recovery for 30 Years: Influence of Management Strategies on Soil Physical Attributes and Organic Matter

  • Authors: Laura Silva Nantes, Carolina dos Santos Batista Bonini, Melissa Alexandre Santos, Lucas da Silva Alves, Josiane Lourencetti, Alfredo Bonini Neto, José Augusto Liberato de Souza, Gabriel Augusto da Silva Lunardelli, Mariana Bonini Silva, Dayara Vivian Alvares, et al.

  • Year: 2025

2. Accumulated Carbon Fractions in Tropical Sandy Soils and Their Effects on Fertility and Grain Yield in an Integrated Crop–Livestock System

  • Authors: Deyvison de Asevedo Soares, Bianca Midori Souza Sekiya, Viviane Cristina Modesto, Allan Hisashi Nakao, Leandro Alves Freitas, Isabela Malaquias Dalto de Souza, J.H.S. Luz, Fernando Shintate Galindo, Gelci Carlos Lupatini, Gustavo Pavan Mateus, et al.

  • Year: 2023

3. Evolution of Soil Chemical Fertility in an Area under Recovery for 30 Years with Anthropic Intervention

  • Authors: Josiane Lourencetti, Carolina dos Santos Batista Bonini, Marcelo Andreotti, Marlene Cristina Alves, Alfredo Bonini Neto, Melissa Alexandre Santos, Vitor Correa de Mattos Barretto, Roberth Wicleff Rodrigues de Figueredo

  • Year: 2023

4. Long-Term Integrated Systems of Green Manure and Pasture Significantly Recover the Macrofauna of Degraded Soil in the Brazilian Savannah

  • Authors: Carolina dos Santos Batista Bonini, Thais Monique de Souza Maciel, Bruno Rafael de Almeida Moreira, José Guilherme Marques Chitero, Rodney Lúcio Pinheiro Henrique, Marlene Cristina Alves

  • Year: 2023

5. Long-Term Integrated Crop–Livestock–Forestry Systems Recover the Structural Quality of Ultisol Soil

  • Authors: Aline Matos, Carolina dos Santos Batista Bonini, Bruno Rafael de Almeida Moreira, Marcelo Andreotti, Reges Heinrichs, Diogo Tiago da Silva, José Augusto Liberato de Souza, Melissa Alexandre Santos, Cristiana Andrighetto, Gustavo Mateus Pavan, et al.

  • Year: 2022

6. Azospirillum Inoculation of ‘Marandu’ Palisade Grass Seeds: Effects on Forage Production and Nutritional Status

  • Authors: Reges Heinrichs, G.C. Meirelles, L.F. de Melo Santos, M.V. da Silva Lira, A. de Marcos Lapaz, M.A. Nogueira, C. dos Santos Batista Bonini, Filho, A. Moreira

  • Year: 2020

7. Can Palisade and Guinea Grass Sowing Time in Intercropping Systems Affect Soybean Yield and Soil Chemical Properties?

  • Authors: N.R. Costa, Marcelo Andreotti, C.A.C. Crusciol, C.M. Pariz, J.W. Bossolani, A.M.D. Castilhos, C.A.C.D. Nascimento, C.G.D.R. Lima, C. dos Santos Batista Bonini, E.E. Kuramae

  • Year: 2020

8. Effect of Sulfur Sources on Megathyrsus Maximus ‘Mombaça’ Grass Cultivated in a Typic Ultisol

  • Authors: L.F. de Melo Santos, A. de Marcos Lapaz, F.V. Ribeiro, I.V. Ribeiro, G.C. Meirelles, M.V. da Silva Lira, C.V. Soares Filho, C. dos Santos Batista Bonini, A.R. dos Reis, A. Moreira, et al.

  • Year: 2020

9. Soil Compaction in Crop-Livestock-Forest Integration Systems of Five Years of Implantation and Use

  • Authors: J.F.D. Souza, C. dos Santos Batista Bonini, G.P. Mateus, C.T. de Souza, R.L.S. Perusso, F.G. Pedro, G.L. Oliverio

  • Year: 2020

10. Spray Nozzles and Droplet Size Effects on Soybean Canopy Deposits and Stink Bugs Control in West Region of São Paulo State – Brazil

  • Authors: M.A.G.L. Farias, C.G. Raetano, R.G. Chechetto, P.J. Ferreira-Filho, J.C. Guerreiro, C.S.B. Bonini, A.C. Firmino, R.C. Lima, E.P. Prado

  • Year: 2020

​






	


	

	






	
	

		


Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award
			

				Published on  by Shen Awards			

		
	


	

		
Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award


Associate Professor from Department of Physiology, China Medical University, Taiwan




















Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.


Professional Profile



Education


Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.


Professional Experience


Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.


Research Interests


Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.


Research Skills


Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.


Awards and Honors


Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.


Conclusion


Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.


Publication Top Notes


M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025


2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025


3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025


4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024


5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024


6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2


7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2


























	


	

	






	
	

		


Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award
			

				Published on  by Shen Awards			

		
	


	

		
Dr. Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award


Deputy Dean from Perdana University, Malaysia 




















Sutha Devaraj is a dedicated researcher and academician with expertise in pharmaceutical sciences, specializing in drug discovery and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences from Universiti Sains Malaysia (USM) in 2018, where her research focused on the development of optimized methods for preparing bioactive fractions of Strobilanthes crispus (L.) Bremek. Her work involved the quantification of the plant’s marker compound, contributing to advancements in natural product-based drug discovery. Before completing her Ph.D., Sutha obtained a Master’s in Pharmacology from USM in 2012. Her master’s thesis focused on the hepatoprotective properties of Curcuma xanthorrhiza Rox, exploring its potential for liver protection through its bioactive compounds. She also holds a B.Sc. (Hons) in Biotechnology from AIMST University, Malaysia, where she graduated with a CGPA of 3.41. This academic foundation in biotechnology provided her with a strong understanding of molecular biology and biochemistry, essential for her later research in pharmacology and drug development. Throughout her career, Sutha has contributed significantly to the study of plant-based compounds with medicinal properties, and her work has enhanced the understanding of their therapeutic potential. Her academic journey has been marked by a consistent focus on integrating practical research with innovative approaches in pharmaceutical sciences.


Professional Profile



Education






































Sutha Devaraj’s educational background is distinguished by her specialized studies in pharmaceutical sciences and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences with a focus on Drug Discovery from Universiti Sains Malaysia (USM) in 2018. Her doctoral thesis, titled Development of an Optimized Method for the Preparation of Bioactive Fraction of Strobilanthes crispus (L.) Bremek and the Quantification of its Marker Compound, was instrumental in advancing research on bioactive compounds derived from natural sources. This work enhanced the understanding of the therapeutic potentials of Strobilanthes crispus, contributing to both pharmaceutical science and ethnomedicine. Before completing her Ph.D., Sutha obtained her Master of Science (M.Sc.) in Pharmacology from USM in 2012. Her research focused on the hepatoprotective and pharmacological properties of Curcuma xanthorrhiza Rox, and she published findings related to the effectiveness of its standardized ethanolic extract in protecting the liver, demonstrating her expertise in pharmacological testing and drug development. Sutha’s academic journey began with a Bachelor of Science (B.Sc.) in Biotechnology (Hons) from AIMST University in 2008, where she graduated with a CGPA of 3.41. This early foundation in biotechnology paved the way for her subsequent advanced studies in pharmacology and pharmaceutical sciences.


Professional Experience


Sutha Devaraj has accumulated significant experience in the field of pharmaceutical sciences and pharmacology. Throughout her career, she has worked with various academic and research institutions, where she has contributed to advancing the understanding of pharmacological mechanisms and drug discovery. As a researcher at Universiti Sains Malaysia (USM), Sutha has actively participated in projects focusing on the isolation and quantification of bioactive compounds from plants, which has led to important findings on their therapeutic potentials. She has collaborated with both local and international researchers to examine the pharmacological properties of natural products, a focus that has shaped her work in drug discovery. In addition to her research roles, Sutha has also contributed to teaching and mentoring undergraduate and postgraduate students. She has shared her expertise in pharmacology and biotechnology, helping shape the next generation of scientists. Through her work, Sutha has built a strong professional reputation, earning recognition for her in-depth understanding of drug development processes and her ability to implement novel methodologies in her research.


Research Skills


Sutha Devaraj possesses a wide array of research skills essential to her work in pharmaceutical sciences and pharmacology. Her proficiency in bioactive compound isolation and quantification has been demonstrated through her research on Strobilanthes crispus and Curcuma xanthorrhiza, both of which are significant to natural drug discovery. She is highly skilled in pharmacological testing, utilizing a range of in-vitro and in-vivo models to assess the therapeutic efficacy of plant-based extracts. In addition to her experimental capabilities, Sutha has expertise in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, which she has used to identify and quantify bioactive compounds in complex matrices. Her background in biotechnology provides her with a solid understanding of biochemical assays, including enzyme inhibition and receptor binding assays. Furthermore, Sutha has honed her skills in data analysis and interpretation, often using sophisticated statistical tools to evaluate research results. Her ability to combine these skills allows her to contribute to cutting-edge research in drug discovery, particularly in exploring new therapeutic agents derived from natural sources.


Research Interests


Sutha Devaraj’s research interests lie at the intersection of pharmacology, drug discovery, and natural products. She is particularly focused on the exploration of plant-based bioactive compounds and their potential applications in pharmaceutical development. Her Ph.D. research on Strobilanthes crispus exemplifies her dedication to the discovery of new therapeutic agents from natural resources. Sutha is passionate about investigating the hepatoprotective and anticancer properties of various plant species, particularly those indigenous to Southeast Asia. She is also interested in the mechanisms of action of these compounds, aiming to elucidate how they interact with biological systems to exert therapeutic effects. In addition to pharmacological studies, Sutha is keen on formulation development, specifically in optimizing methods for the preparation and stabilization of bioactive extracts. Her future research endeavors include furthering the development of natural-based drugs with fewer side effects compared to conventional synthetic drugs, contributing to a more sustainable and effective approach in pharmaceutical therapy.


Awards and Honors


Sutha Devaraj’s career has been marked by notable recognition for her academic and research contributions. She was awarded a PhD Fellowship by Universiti Sains Malaysia (USM), providing her with the opportunity to carry out high-impact research in the field of pharmaceutical sciences. Additionally, her M.Sc. research on Curcuma xanthorrhiza earned her accolades for its significance in hepatoprotective studies. Sutha’s ability to combine scientific rigor with practical applications has led to her work being published in well-respected, peer-reviewed journals. Her academic excellence and contributions to the field have earned her membership in several prestigious academic organizations and editorial positions in prominent journals related to pharmacology and drug development. Her work continues to be recognized by the academic community, highlighting her as an emerging leader in her field of expertise.


Conclusion


In conclusion, Sutha Devaraj is an accomplished researcher with a strong academic background and expertise in pharmacology and drug discovery. Her dedication to advancing natural product research has led to valuable contributions in the areas of bioactive compound isolation and pharmacological evaluation. Sutha’s research skills, which include advanced analytical techniques and experimental methodologies, equip her to make meaningful advances in the development of therapeutic agents. Her research interests reflect a deep commitment to exploring sustainable and effective natural-based drugs, particularly those with hepatoprotective and anticancer properties. With a growing reputation in the field, Sutha’s work continues to inspire innovation in the pharmaceutical sciences, and her achievements and contributions make her a prominent figure in the ongoing search for new, safer therapeutic options.


Publications Top Notes


1. Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb


    

  • 

    Authors: S. Devaraj, A.S. Esfahani, S. Ismail, S. Ramanathan, M.F. Yam
    

    • 

  • 

    Journal: Molecules, 15(4), 2925–2934
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 97
    

    • 



2. Investigation of Antioxidant and Hepatoprotective Activity of Standardized Curcuma xanthorrhiza Rhizome in Carbon Tetrachloride‐Induced Hepatic Damaged Rats


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, M.F. Yam
    

    • 

  • 

    Journal: The Scientific World Journal, 2014(1), 353128
    

    • 

  • 

    Year: 2014
    

    • 

  • 

    Citations: 75
    

    • 



3. Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, S. Marimuthu, Y.M. Fei
    

    • 

  • 

    Journal: Journal of Medicinal Plants Research, 4(23), 2512–2517
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 53
    

    • 



4. Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of S. crispus in NMU-Induced Rat Model


    

  • 

    Authors: N.S. Yaacob, H.M. Yankuzo, S. Devaraj, J.K.M. Wong, C.S. Lai
    

    • 

  • 

    Journal: PLoS One, 10(5), e0126426
    

    • 

  • 

    Year: 2015
    

    • 

  • 

    Citations: 41
    

    • 



5. A Study on the Hepatoprotective Effect of Andrographis paniculata (Burm. F) Nees on Mice


    

  • 

    Author: D. Sutha
    

    • 

  • 

    Journal: Journal of Phytology, 2(11)
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 35
    

    • 



6. In Vivo Toxicological Investigations of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb. Rhizome


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, M. FeiYam
    

    • 

  • 

    Journal: Journal of Natural Products and Plant Resources, 3(1), 67–73
    

    • 

  • 

    Year: 2013
    

    • 

  • 

    Citations: 28
    

    • 



7. Explorations of CRISPR/Cas9 for Improving the Long-Term Efficacy of Universal CAR-T Cells in Tumor Immunotherapy


    

  • 

    Authors: M. Naeem, A. Hazafa, N. Bano, R. Ali, M. Farooq, S.I. Abd Razak, T.Y. Lee, et al.
    

    • 

  • 

    Journal: Life Sciences, 316, 121409
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 23
    

    • 



8. Phytochemical, Antioxidant, Antipyretic and Anti-inflammatory Activities of Aqueous-Methanolic Leaf Extract of Mangifera indica


    

  • 

    Authors: Q.U. Ain, M.O. Iqbal, I.A. Khan, N. Bano, M. Naeem, M.I. Jamaludin, S. Devaraj
    

    • 

  • 

    Journal: American Journal of Translational Research, 15(7), 4533
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 15
    

    • 



9. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients


    

  • 

    Authors: M. Naeem, N. Bano, S. Manzoor, A. Ahmad, N. Munawar, S.I.A. Razak, T.Y. Lee, et al.
    

    • 

  • 

    Journal: Biomolecules, 13(1), 99
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 10
    

    • 



10. Innovative Aspects and Applications of Single Cell Technology for Different Diseases


    

  • 

    Authors: A. Ali, S. Manzoor, T. Ali, M. Asim, G. Muhammad, A. Ahmad, M.I. Jamaludin, et al.
    

    • 

  • 

    Journal: American Journal of Cancer Research, 14(8), 4028
    

    • 

  • 

    Year: 2024
    

    • 

  • 

    Citations: 1
    

    • 



11. Understanding the Role of Pharmacology and Toxicology in the Research, Development, and Innovation Process by Analyzing the Drug Development Process


    

  • 

    Authors: L. Waheed, I. Ur Rehman, S. Devaraj, F.H.G.Q. Al-Amier, P. Jativa, G. Naz, et al.
    

    • 

  • 

    Journal: Journal of Pharmaceutical Negative Results, Vol. 14
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 1
    

    •